| Literature DB >> 29423407 |
Bernd Fink1,2, Florian Sevelda1,3.
Abstract
Periprosthetic joint infection (PJI) is one of the most frequent reasons for painful shoulder arthroplasties and revision surgery of shoulder arthroplasties. Cutibacterium acnes (Propionibacterium acnes) is one of the microorganisms that most often causes the infection. However, this slow growing microorganism is difficult to detect. This paper presents an overview of different diagnostic test to detect a periprosthetic shoulder infection. This includes nonspecific diagnostic tests and specific tests (with identifying the responsible microorganism). The aspiration can combine different specific and nonspecific tests. In dry aspiration and suspected joint infection, we recommend a biopsy. Several therapeutic options exist for the treatment of PJI of shoulder arthroplasties. In acute infections, the options include leaving the implant in place with open debridement, septic irrigation with antibacterial fluids like octenidine or polyhexanide solution, and exchange of all removable components. In late infections (more than four weeks after implantation) the therapeutic options are a permanent spacer, single-stage revision, and two-stage revision with a temporary spacer. The functional results are best after single-stage revisions with a success rate similar to two-stage revisions. For single-stage revisions, the microorganism should be known preoperatively so that specific antibiotics can be mixed into the cement for implantation of the new prosthesis and specific systemic antibiotic therapy can be applied to support the surgery.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29423407 PMCID: PMC5750516 DOI: 10.1155/2017/4582756
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Resection arthroplasty.
| Authors |
| Follow-up (years) | Systemic antibiotic treatment | Freedom from infection (%) | Score |
|---|---|---|---|---|---|
| Braman et al. 2006 [ | 7 | 1.7 | 100 | ||
| Coste et al. 2004 [ | 10 | 2.8 | No information | 70 | 30 CS |
| Rispoli et al. 2007 [ | 13 | 8.3 | No information | 100 | |
| Sperling et al. 2001 [ | 21 | 71.4 | |||
| Debeer et al. 2006 [ | 7 | 0.9 | 26 CS | ||
| Verhelst et al. 2011 [ | 11 | 1.9 | 46 CS | ||
| Ghijselings et al. 2013 [ | 6 | 2.1 | 28 CS | ||
| Weber et al. 2011 [ | 5 | 4 | 100 | 33 CS | |
| Romanò et al. 2012 [ | 6 | 3.5 | 100 | 32 CS |
Permanent spacer.
| Authors |
| Follow-up (years) | Systemic antibiotic treatment | Local antibiotic treatment | Freedom from infection (%) | Score |
|---|---|---|---|---|---|---|
| Coffey et al. 2010 [ | 4 | 1.8 | Gentamicin | 100 | 57 CS | |
| Coste et al. 2004 [ | 3 | 2.8 | No information | No information | 100 | 38 CS |
| Jerosch and Schneppenheim 2003 [ | 2 | 100 | ||||
| Themistocleous et al. 2007 [ | 4 | 100 | ||||
| Stine et al. 2010 [ | 15 | 2.4 | 100 | 50 DASH | ||
| Ghijselings et al. 2013 [ | 4 | 3.3 | 21 CS | |||
| Romanò et al. 2012 [ | 15 | 3 | 93.3 | 34 CS | ||
| Mahure et al. 2016 [ | 9 | 4 | 100 | 57 ASES |
Figure 1Two-stage revision.
| Authors |
| Follow-up (years) | Systemic antibiotic treatment | Local antibiotic treatment | Freedom from infection | Score |
|---|---|---|---|---|---|---|
| Coffey et al. 2010 [ | 12 | 1.8 | Gentamicin | 100 | 57 CS | |
| Coste et al. 2004 [ | 10 | 2.8 | No information | No information | 60 | 35 CS |
| Cuff et al. 2008 [ | 10 | 100 | ||||
| Jerosch and Schneppenheim 2003 [ | 8 | 100 | ||||
| Mileti et al. 2004 [ | 4 | 7.4 | 100 | |||
| Seitz Jr. and Damacen 2002 [ | 5 | 4.8 | 100 | |||
| Sperling et al. 2001 [ | 3 | 100 | ||||
| Stine et al. 2010 [ | 12 | 2.4 | 100 | |||
| Strickland et al. 2008 [ | 19 | 63.2 | ||||
| Weber et al. 2011 [ | 4 | 4 | 100 | 40 CS | ||
| Romanò et al. 2012 [ | 17 | 3.8 | 100 | 38 CS | ||
| Buchalter et al. 2017 [ | 19 | 5.25 | 78 | 69 ASES | ||
| Li et al. 2016 [ | 8 | 1.65 | 100 | 53 CS |
Figure 2One-stage revision.
| Authors |
| Follow-up | Systemic antibiotic treatment | Local antibiotic treatment | Freedom from infection | Score |
|---|---|---|---|---|---|---|
| Coste et al. 2004 [ | 3 | 2.8 | No information | No information | 100 | 66 CS |
| Cuff et al. 2008 [ | 7 | 100 | ||||
| Ince et al. 2005 [ | 16 | 5.7 | 100 | 33,6 CS | ||
| Sperling et al. 2001 [ | 2 | 50 | ||||
| Beekman et al. 2010 [ | 11 | 0.9 | 90,9 | 51 CS | ||
| Klatte et al. 2013 [ | 35 | 2.7 | 94 | 51 CS |